Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and SYN2510's potential in cancer treatments.
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising? This drugmaker's lead candidate could become a top-selling cancer therapy.
2 Stocks Up Over 700% in 2024 That Could Soar Even Further These relatively small companies are developing new cancer therapies that could generate billions in annual sales.
TIL Stock Earnings: Instil Bio Beats EPS for Q2 2024 TIL stock results show that Instil Bio beat analyst estimates for earnings per share the second quarter of 2024.
TIL Stock Earnings: Instil Bio Beats EPS for Q4 2023 TIL stock results show that Instil Bio beat analyst estimates for earnings per share the fourth quarter of 2023.
TIL Stock Earnings: Instil Bio Beats EPS for Q2 2023 TIL stock results show that Instil Bio beat analyst estimates for earnings per share the second quarter of 2023.
Here's Why Everyone's Talking About Summit Therapeutics Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock.
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher? A candidate that Instil Bio in-licensed this August is similar to a candidate that recently outperformed the world's top-selling cancer therapy.
Week In Review: ImmuneOnco Out-Licenses Two Antibodies In $2 Billion Deal Shanghai ImmuneOnco Biopharma out-licensed global rites (ex-China) for two of its antibodies to Instil Bio of Dallas, Texas. ImmuneOnco will receive an upfront and near-term payments of $50 million, and up to more than $2 billion in milestones.
TIL Stock Earnings: Instil Bio Misses EPS for Q1 2024 TIL stock results show that Instil Bio missed analyst estimates for earnings per share the first quarter of 2024.
TIL Stock Earnings: Instil Bio Misses EPS for Q1 2023 TIL stock results show that Instil Bio missed analyst estimates for earnings per share the first quarter of 2023.
TIL Stock Earnings: Instil Bio Misses EPS for Q3 2023 TIL stock results show that Instil Bio missed analyst estimates for earnings per share the third quarter of 2023.
Why Shares Of Chinese Companies Are Trading Lower? Here Are 54 Stocks Moving In Wednesday's Mid-Day Session Gainers Kala Pharmaceuticals, Inc. (
NASDAQ: KALA ) shares gained 130.5% to $9.03 after the company announced FDA acceptance of a IND application for its KPI-012 for the treatment of persistent corneal epithelial defect.
